Phase 2a Dose-Rising, Safety, Tolerability, and Efficacy Study of Topical SOR007 for Cervical Intraepithelial Neoplasia (CIN)
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 主要终点
- Incidence of treatment emergent adverse events
研究概览
简要总结
This is a Phase 2, open-label, dose-rising study evaluating the safety, tolerability, and preliminary efficacy of three concentrations of SOR007 ointment (0.15%, 1.0%, and 2.0%) applied topically once per week for four weeks to the ectocervix of subjects with high grade cervical intraepithelial neoplasia (CIN).
详细描述
In this Phase 2, open-label, dose-rising study, subjects with high grade (CIN 2 or 3) CIN will receive once-weekly topical application of SOR007 ointment to the ectocervix for four weeks. Subjects will be enrolled in three dose-escalating cohorts of three subjects assigned consecutively to receive 0.15%, 1.0%, or 2.0% SOR007 ointment. At the final study visit (Visit 7) subjects will undergo an excision or punch biopsy to record the stage of CIN. PK samples will be obtained post-application on Day 0 at 1, 2, 4, 6, and 24 hours' post-application on Day 1. Additional PK samples will be collected at each visit. Plasma samples for PK analysis on Days 7, 14 and 21 will be collected prior to SOR007 application.
The Medical Monitor will review all available data prior to dose escalation. Dose-escalation of SOR007 will be determined by the Medical Monitor. This will be repeated for each escalated dose until all dose levels have been enrolled or a dose is determined unsafe. Safety will be assessed in an ongoing manner and formal safety reviews will be conducted twice for each cohort: after Day 14 and after Day 49 of the last subject in the cohort. If a safety or tolerability issue becomes apparent in a cohort, an additional three subjects will be enrolled at that dose level, for a maximum of six subjects in that cohort. If ≥ 1 safety or tolerability issue occurs in the additional 3 subjects, the prior dose-level will be determined to be the highest dose with an acceptable safety and tolerability profile. If no further safety and tolerability issues are identified in the expanded cohort, dose-escalation will continue.
Once the highest dose with an acceptable safety and tolerability profile has been determined by the Medical Monitor, PI, and Sponsor Medical Director, a further 3 subjects will be enrolled to that dose level in order to increase the subject numbers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent;
- •Female adults ≥ 18 years of age;
- •Presence of newly diagnosed (within 8 weeks prior to administration of SOR007), histologically confirmed CIN 2, CIN 2/3 or CIN 3;
- •Candidate for observation, treatment, or removal of CIN;
- •Satisfactory colposcopy (visualization of the entire squamocolumnar junction and margins of any visible lesions);
- •Appropriate contraception throughout study period;
排除标准
- •Pap smear and/or colposcopy suspicious for invasive disease;
- •History of previous conization/LEEP;
- •History of toxic shock syndrome;
- •Known allergy or prior intolerance to paclitaxel;
- •Immunodeficiency (including HIV/AIDS and immunosuppressive medication);
- •Current, reported participation in another experimental, interventional protocol;
- •Active lower genital infection(s);
- •Malignant disease at the time of inclusion, with the exclusion of basal cell carcinoma (BCC) or dermal carcinoma-in-situ;
- •Concurrent treatment with cytotoxic, radiation, immune-stimulative, or immune-suppressive therapy, or with systemic corticosteroid dose of > 5 mg/d or prednisone (or its equivalent);
- •Concomitant use of topical vaginal medications or products;
- •Pregnant or lactating;
- •Pregnancy planned within six (6) months following study drug application;
- •Significant acute or chronic medical or psychiatric illness or other environmental or social factors that, in the opinion of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study
研究组 & 干预措施
SOR007 0.15%
1 mL of 0.15% SOR007 Ointment
干预措施: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (Drug)
SOR007 1.0%
1 mL of 1.0% SOR007 Ointment
干预措施: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (Drug)
SOR007 2.0%
1 mL of 2.0% SOR007 Ointment
干预措施: SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment (Drug)
结局指标
主要结局
Incidence of treatment emergent adverse events
时间窗: 49 days
Treatment emergent adverse events will include all reported adverse events, laboratory assessments, physical examination findings, and vital signs.
次要结局
- Regression of CIN(Baseline and 49 days)
- Pharmacokinetics: Area under the plasma concentration versus time curve (AUC) of SOR007(49 days)
- Pharmacokinetics: Peak plasma concentration (Cmax) of SOR007(49 days)
- Pharmacokinetics: Time at which peak plasma concentration is observed (Tmax) of SOR007(49 days)